BOSTON (Reuters)—Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday. The report, released by Democratic Senator Claire McCaskill, said those efforts led to an Insys employee making misleading statements…
Arizona Accuses Insys of Fraudulent Opioid Marketing Scheme
(Reuters)—Arizona’s attorney general sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine. The lawsuit by Arizona Attorney General Mark Brnovich in Maricopa County Superior Court in Phoenix comes during a series of federal and state investigations centered on…
S.C. Sues Purdue, Maker of OxyContin, Over Deceptive Marketing
(Reuters)—On Tuesday, South Carolina sued Purdue Pharma LP, becoming the latest state or local government to accuse the OxyContin maker of deceptive marketing practices that have contributed to a national opioid addiction epidemic. The lawsuit by South Carolina Attorney General Alan Wilson, filed in Richland County Court of Common Pleas in Columbia, accuses the company…
Overlooking HIPAA Risks Can Lead to Costly Breach
Is your office at risk? Are all your business associate agreements (BAAs) in place, and is your office HIPAA compliant? As promised, and as part of its continued efforts to assess and enforce compliance with the HIPAA Privacy, Security and Breach Notification Rules, the Health and Human Services (HHS) Office for Civil Rights (OCR) continues…
Prepare Now to Sell Your Medical Practice
Selling a medical practice can be a lucrative endeavor. One of the most important phases of any sale transaction is the due diligence process. During this phase, a potential buyer and their advisors have the opportunity to examine the seller’s books, records and files in great detail to ensure that the buyer is comfortable purchasing…
New Hampshire Sues Purdue Pharma over Opioid Marketing
(Reuters)—New Hampshire sued OxyContin maker Purdue Pharma LP on Tuesday, joining several state and local governments in accusing the drugmaker of engaging in deceptive marketing practices that have helped fuel a national opioid addiction epidemic. The lawsuit filed in Merrimack County Superior Court claimed that Purdue Pharma significantly downplayed the risk of addiction posed by…
U.S. Governors Urge Trump to Make Health Insurance Payments
WASHINGTON (Reuters)—Democratic and Republican U.S. governors on Wednesday urged the Trump administration, as well as Congress, to continue funding payments to health insurance companies that make Obamacare plans affordable, calling it critical to stabilizing the insurance marketplace. In a statement, governors joined insurers pressuring Republican President Donald Trump to stand down from threats to cut…
U.S. Launches Opioid Fraud and Detection Unit
(Reuters)—U.S. Attorney General Jeff Sessions unveiled on Wednesday a plan to go after doctors and pharmacies suspected of healthcare fraud by over-prescribing and unbridled distribution of addictive pain medications known as opioids. In a speech at a Columbus, Ohio, police academy, Sessions said a new Opioid Fraud and Abuse Detection Unit pilot program would also…
U.S. Senator Expands Opioid Probe to Distributors, Drugmakers
(Reuters)—U.S. Democratic Senator Claire McCaskill on Thursday expanded an investigation into the causes of the opioid crisis plaguing the country, seeking information from four more drugmakers and three drug distributors. The top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee is focusing on the distribution of opioids and the efforts companies made to…
Mallinckrodt Settles U.S. Opioid Drug Probe for $35 million
(Reuters)—Mallinckrodt Plc., one of the largest manufacturers of the generic opioid painkiller oxycodone, will pay $35 million to resolve allegations that it failed to report suspicious drug orders, the U.S. Justice Department said on Tuesday. The deal, in which Mallinckrodt did not admit wrongdoing, marked a record settlement of claims that a drugmaker failed to properly…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 18
- Next Page »